# Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

> **NCT00985192** · PHASE2 · COMPLETED · sponsor: **Translational Oncology Research International** · enrollment: 49 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** everolimus
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00985192
- **Lead sponsor:** Translational Oncology Research International
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-08-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985192, "Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00985192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*